William Blair analyst Matt Phipps has reiterated their bullish stance on NAMS stock, giving a Buy rating today.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matt Phipps has given his Buy rating due to a combination of factors tied to NewAmsterdam’s lead asset, obicetrapib, and the company’s clinical and regulatory momentum. He views the PREVAIL cardiovascular outcomes study as progressing well, with event rates closely mirroring those seen in the earlier BROADWAY trial, which had previously demonstrated a meaningful reduction in risk. Because the patient characteristics in PREVAIL and BROADWAY are highly comparable, he interprets the similar event dynamics as a constructive signal for potentially replicating BROADWAY’s efficacy. In addition, management has committed to clarifying the exact timing of the PREVAIL readout around midyear, which should serve as a key catalyst for investors.
Phipps also emphasizes 2026 as a pivotal inflection year for the company, with the first anticipated European approval of obicetrapib, a likely U.S. NDA submission, and multiple additional trial readouts (including RUBENS and VINCENT) that could expand the drug’s commercial opportunity. Despite a strong share-price performance over the past six months that has outpaced the broader biotech index, he believes current valuation still does not fully capture the long-term revenue potential of a drug he views as a prospective blockbuster. The combination of a de-risking clinical profile, approaching regulatory milestones, and continued upside relative to peers underpins his decision to maintain a positive stance on the stock. Accordingly, he reiterates his Buy (Outperform) recommendation on NewAmsterdam Pharma.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $52.00 price target.